; (C) identification of key regulatory science and policy issues critical to advancing development of safe and effective drugs; and (D) engagement by staff of the relevant centers of the Food and Drug Administration and other relevant offices of the Food and Drug Administration and National Institutes of Health with the designated leadership of the Collaborative. 5. Rare Neurodegenerative Disease Grant Program The Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall carry out a program of awarding grants to, and contracts entered into with, public and private entities to cover the costs of research on and development of interventions intended to prevent, diagnose, mitigate, treat, or cure amyotrophic lateral sclerosis and other life-threatening or severely debilitating neurodegenerative diseases, including costs incurred with respect to the development and critical evaluation of tools, methods, and processes— (1) to characterize such neurodegenerative diseases and their natural history; (2) to identify molecular targets for such neurodegenerative diseases; and (3) to increase efficiency and productivity of clinical development of therapies, including advancing rational therapeutic development and working to establish clinical trial networks. 6. Authorization of appropriations For purposes of carrying out this Act, there are authorized to be appropriated $100,000,000 for each of fiscal years 2022 through 2026.